Skip to main content
Elsevier BV

Financial Contracting in Biotech Strategic Alliances

Preprints
Robinson, DT; Stuart, TE
2002

We conduct a detailed analysis of 125 strategic alliance contracts, all of which concern early-stage, genomics-based research at small, biotechnology R&D companies. Staged investment is ubiquitous, but solutions to agency problems vary. The cycle of equity participation in alliances resembles what we observe in venture capital contracts: they involve convertible equity and sometimes contain anti-dilution provisions, warrants, and board seats. Contracts contain explicit provisions linking equity participation to subsequent IPOs and contain clauses designed to insulate both parties from multi-tasking problems. Contrary to the standard assumptions of static contract theory, contracts often specify provisions that are unobservable or difficult to verify.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

DOI

Publication Date

2002
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Robinson, D. T., & Stuart, T. E. (2002). Financial Contracting in Biotech Strategic Alliances. Elsevier BV. https://doi.org/10.2139/ssrn.327881
Robinson, David T., and Toby E. Stuart. “Financial Contracting in Biotech Strategic Alliances.” Elsevier BV, 2002. https://doi.org/10.2139/ssrn.327881.
Robinson DT, Stuart TE. Financial Contracting in Biotech Strategic Alliances. Elsevier BV. 2002.
Robinson, David T., and Toby E. Stuart. “Financial Contracting in Biotech Strategic Alliances.” Elsevier BV, 2002. Crossref, doi:10.2139/ssrn.327881.
Robinson DT, Stuart TE. Financial Contracting in Biotech Strategic Alliances. Elsevier BV. 2002.

DOI

Publication Date

2002